The company faces imminent liquidity pressure and will likely need to raise capital in the near term, which would be highly dilutive given the $4M market cap. Traders should watch for any financing announcements, partnership deals, or strategic alternatives. The stock may also be at risk of delisting if it cannot meet Nasdaq continued listing standards.
Price Chart
Executive Summary
Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in cash, down from $8.5M at year-end 2025. Operating cash burn was $7.0M in the quarter, and the company explicitly states it will need additional capital to continue operations, with no assurance of financing. Combined with a management transition and a pause in clinical trial enrollment, the filing signals a severe near-term funding risk for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Cash and cash equivalents fell from $8.5M (Dec 31, 2025) to $1.5M (Mar 31, 2026), a decline of $7.0M in one quarter.
- Net cash used in operating activities was $7.0M for Q1 2026, compared to $5.0M in Q1 2025.
- No financing activity occurred in Q1 2026, versus $3.2M raised in Q1 2025.
- Net loss improved to $2.5M from $4.5M year-over-year, but loss per share fell from $9.11 to $0.23 due to a massive increase in weighted-average shares outstanding (10.96M vs 0.50M).
- The company states it will need to raise additional capital and there can be no assurance such financing will be available.
- Executive management transition (new CEO Junyi Dai) and a reassessment of development priorities are underway.
- All outstanding Series AA and AAA preferred stock converted into common stock during Q1 2026.
- The company paused enrollment in its Phase 1 combination study pending further evaluation.
Financial Impact
Cash burn of $7.0M in Q1 2026 left only $1.5M, implying less than one quarter of runway without additional funding.
Risk Factors
- Going concern risk if additional financing is not secured within months.
- Severe dilution from any equity or convertible financing.
- Potential Nasdaq delisting if market cap or bid price falls below thresholds.
- Clinical pipeline uncertainty: the Phase 1 trial is paused and development priorities are being reassessed.
- Management transition adds execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023344 |
| Document: form8-k.htm | 0001493152-26-023344 |
| Document: 0001493152-26-023344-index-headers.html | 0001493152-26-023344 |
| Document: 0001493152-26-023344-index.html | 0001493152-26-023344 |
| Document: 0001493152-26-023344.txt | 0001493152-26-023344 |
| 8-K Data (Synthetic) | 0001493152-26-023344 |
Track record
20 reports on INDP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers